title: Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma.
abstract: OBJECTIVE
  Various chemotherapeutic regimens have been applied for treatment of mucosa-associated lymphoid tissue (MALT) lymphoma, but no standard regimen has been identified to date. In view of the activity of oxaliplatin (L-OHP) in various types of lymphoma, we performed a phase II study to evaluate the activity of L-OHP for treatment of MALT lymphoma. The primary objective of this study was to determine the objective response rate according to WHO standard criteria.
  
  
  METHODS
  A total of 16 patients with MALT lymphoma of various sites of origin (four of the ocular adnexa, five of the salivary glands, three of the stomach, two of the lung, and one of the colon and the breast) were administered L-OHP at a dose of 130 mg/m2 infused during 2 hours every 3 weeks. Restaging was performed every two cycles; treatment was continued until complete remission (CR) or for a maximum of six cycles in responders.
  
  
  RESULTS
  Sixty-five cycles were administered (median, four; range, two to six); toxicity consisted of transient sensory neuropathy in eight patients and nausea/emesis WHO grade 2 in two patients, whereas hematologic adverse effects (thrombocytopenia and leukocytopenia grade 2) occurred in only one patient each. Fifteen patients responded to chemotherapy, with nine achieving CR (56%), six (37.5%) achieving partial response, and one achieving stable disease; the median time to response was 4 months (range; 2 to 4 months).
  
  
  CONCLUSIONS
  These data suggest L-OHP is a highly active agent for treatment of MALT lymphoma. However, a longer follow-up is needed to judge whether these remissions are durable.
authors.affiliation: Department of Medicine I, University of Vienna, Vienna, Austria. markus.raderer@meduniwien.ac.at
authors.forename: Markus
authors.initials: M
authors.lastname: Raderer
authors.forename: Stefan
authors.initials: S
authors.lastname: Wöhrer
authors.forename: Rupert
authors.initials: R
authors.lastname: Bartsch
authors.forename: Gerald
authors.initials: G
authors.lastname: Prager
authors.forename: Johannes
authors.initials: J
authors.lastname: Drach
authors.forename: Michael
authors.initials: M
authors.lastname: Hejna
authors.forename: Alexander
authors.initials: A
authors.lastname: Gaiger
authors.forename: Karl
authors.initials: K
authors.lastname: Turetschek
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jaeger
authors.forename: Berthold
authors.initials: B
authors.lastname: Streubel
authors.forename: Christoph C
authors.initials: CC
authors.lastname: Zielinski
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001317:Austria / Q000453:epidemiology; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011446:Prospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin